Pressure is building on pharma and biotech companies to take climate action
As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make environmental sustainability a core part of their business.
Globally, large public biotech and pharmaceutical companies are responsible for more than 200 million metric tons of carbon dioxide and equivalent emissions, according to estimates from one 2022 report. The bulk of those emissions are tied to companies’ products and supply chains, which can be hard to measure. In the U.S., about 8.5% of the national carbon footprint can be attributed to the health care industry at large.
Read Original Article: Pressure is building on pharma and biotech companies to take climate action »
